Table 1.

Characterization of the cell lines

Cell lineMutation/alteration in MAPK pathwaySensitivity to vemurafenibAKT/PI3K mutation or amplification
M229BRAFSAKT1 amplification, heterozygous PTEN
M229AR9BRAFRAKT1 amplification, heterozygous PTEN
M233BRAFRAKT1 amplification, PTEN null
M238BRAFSHeterozygous PTEN
M238AR2BRAFRHeterozygous PTEN
M249BRAFSAKT2 amplification, PTEN null
M255BRAFRAKT2 amplification
M262BRAFSAKT1 mutation
M263BRAFS
M297BRAFS
M299BRAFR
M308BRAFRAKT2 amplification
M370BRAFR
M381BRAFR
M383BRAFR
M395BRAFS
M397BRAFSPTEN null
M399BRAFRPTEN null
M406BRAFS
M407BRAFS
M409BRAFS
M409ARBRAFR
M410BRAFR
M411BRAFSPTEN null
M414BRAFR
M417BRAFR
M397ARBRAF/(truncated BRAF)RPTEN null
M249ARBRAF/NRASRAKT2 amplification, PTEN null
M376BRAF/NRASR
M398BRAF/NRASR
M418KRASNA
M202NRASNA
M207NRASNAHeterozygous PTEN
M243NRASNA
M244NRASNA
M245NRASNA
M296NRASNA
M311NRASNA
M318NRASNAPI3KCA mutation
M408NRASNA
M412ANRASNA
M412BNRASNA
SBCL2NRASNA
SKMEL173NRASNA
WM1366NRASNA
M230WTNA
M257WTNA
M285WTNA
M368WTNA
M375WTNA
PBWTNA

Abbreviations: AR, acquired resistance; WT, BRAF and NRAS wild-type; S, sensitive; R, resistant; NA, not applicable.